Next Add-On Antiepileptic Medication for Refractory Partial Seizures
For a patient on levetiracetam (Keppra) 1500 mg twice daily with inadequate seizure control, add either lamotrigine, oxcarbazepine, or zonisamide as the next agent, with lamotrigine being preferred for its favorable tolerability profile and lack of drug interactions with levetiracetam.
Rationale Based on Evidence
The 2004 American Academy of Neurology/American Epilepsy Society guideline 1 establishes that multiple newer antiepileptic drugs demonstrate efficacy as add-on therapy for refractory partial epilepsy. The key consideration here is that your patient is already on levetiracetam at 3000 mg/day total (1500 mg BID), which represents the maximum recommended dose per FDA labeling 2. Since doses above 3000 mg/day show no additional benefit 2, dose escalation is not an option—you need a second agent.
Specific Drug Recommendations
First-Line Add-On Options:
Lamotrigine (not directly discussed in provided evidence but standard practice):
- Excellent tolerability profile
- No pharmacokinetic interactions with levetiracetam 2
- Broad-spectrum efficacy
- Start low (25 mg daily) and titrate slowly to avoid rash
Oxcarbazepine 1:
- 50% responder rate at 2400 mg/day dose
- Dose-dependent efficacy (600 mg: 26.8%, 1200 mg: 41.2%, 2400 mg: 50% responder rates)
- Common adverse effects: somnolence, dizziness, ataxia, hyponatremia
- Caution: High discontinuation rates at higher doses (67% at 2400 mg/day)
- Start at 600 mg/day and titrate based on tolerance
Zonisamide 1:
- 43% responder rate at 400 mg/day
- Lower discontinuation rates (10%) compared to oxcarbazepine
- Adverse effects: fatigue, dizziness, somnolence, anorexia
- Caution: Risk of renal calculi, psychiatric symptoms
- Start at 100 mg/day
Why These Choices?
The guideline 1 emphasizes that levetiracetam combinations with agents enhancing GABAergic or reducing glutamatergic neurotransmission show particularly strong enhancement 3. Preclinical data demonstrates that levetiracetam's novel mechanism of action provides additive benefit when combined with other AEDs without pharmacokinetic interactions 3.
Critical Dosing Considerations
Your patient is already at maximum levetiracetam dose (3000 mg/day total) 2. The FDA label explicitly states: "Doses greater than 3000 mg/day have been used in open-label studies...There is no evidence that doses greater than 3000 mg/day confer additional benefit" 2.
Important Caveats
- Start low, go slow: The guideline 1 emphasizes that slower titration is better tolerated across all AEDs
- Push to maximal tolerated dose: Efficacy increases with dose for most agents, but balance against side effects
- No pharmacokinetic interactions: Levetiracetam does not affect metabolism of other AEDs 2, making combinations straightforward
- Monitor for behavioral changes: Levetiracetam can cause mood/behavioral problems 2, which may be compounded by polytherapy
What to Avoid
Do not add phenytoin or phenobarbital as first-line add-ons—these older agents have worse tolerability profiles and more drug interactions, though the evidence shows levetiracetam doesn't interact with them pharmacokinetically 2.
Monitoring Strategy
- Assess seizure frequency at 4-8 weeks after reaching target dose of add-on agent
- Monitor for additive CNS side effects (somnolence, dizziness)
- Check sodium levels if using oxcarbazepine
- Screen for mood/behavioral changes with any combination